Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

Locati, Laura D.; Bossi, Paolo; Perrone, Francesco; Potepan, Paolo; Crippa, Flavio; Mariani, Luigi; Casieri, Paola; Orsenigo, Marta; Losa, Marco; Bergamini, Cristiana; Liberatoscioli, C.; Quattrone, Pasquale; Calderone, Rosa Gioia; Rinaldi, Gaetana; Pilotti, Silvana; Licitra, Lisa

doi:10.1016/j.oraloncology.2008.07.010

Cited by 191 publications

(133 citation statements)

References 18 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Recently, EGFR inhibitors, such as cetuximab, have increasingly been used to treat salivary gland tumors, which are often resistant to chemotherapy or radiotherapy. Cetuximab-based regimens were used in a phase II study including 30 patients with recurrent or metastatic salivary gland carcinomas, and >50% of the treated patients achieved SD (20). Thus, cetuximab is being increasingly recognized as a more effective alternative to conventional chemotherapy.…”

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 99%

“…Additionally, 50-70% of SDCs express epidermal growth factor receptor (EGFR; HER1) (17)(18)(19), and anti-EGFR-targeted therapies, such as cetuximab, are expected to be useful as novel SDC treatments. Locati (20). However, the role of molecularly targeted therapies in the treatment of salivary gland carcinomas has not been well defined, and combination therapy comprising cisplatin/5-fluorouracil (5-FU) plus cetuximab has not been tested in SDC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Kawahara

Hiraki

Yoshida

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Salivary duct carcinoma is a highly aggressive disease with a poor prognosis. Surgical resection is currently the only curative treatment, as there is no effective systemic therapy for this malignancy. Recently, trastuzumab has been shown to exhibit therapeutic efficacy in the treatment of salivary duct carcinoma; similarly, molecularly targeted agents, such as cetuximab, are expected to be useful for salivary duct carcinoma treatment. We herein describe the case of a 56-year-old man diagnosed with salivary duct carcinoma in the left submandibular region, with ipsilateral multiple metastases to the neck lymph nodes. Radical resection of the tumor and submandibular gland with neck dissection were performed. One month after radical surgery, computed tomography (CT) scans indicated metastasis in the lower lobe of the left lung. CT-guided transthoracic fine-needle aspiration biopsy revealed a single metastasis and lung metastasectomy was immediately performed. The tumor cells of the primary lesion and those of the lung metastasis were immunohistochemically positive for epidermal growth factor receptor. One month later, multiple right lung metastases appeared, and the patient was treated with cisplatin/5-fluorouracil (5-FU) chemotherapy plus cetuximab, achieving a complete radiographic response. However, multiple lung metastases developed during adjuvant weekly cetuximab monotherapy. Subsequently, treatment with S-1 and weekly cetuximab was initiated, and the multiple lung metastases have been maintained as stable disease for 5 months. To the best of our knowledge, this is the first report of cetuximab use for the treatment of salivary duct carcinoma. Although cisplatin/5-FU chemotherapy plus cetuximab was efficacious in treating the lung metastasis, cetuximab monotherapy was insufficient for controlling tumor growth.

show abstract

Section: Sdc Was First Described In 1968 Bymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Kawahara

Hiraki

Yoshida

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…None of the patients had an objective tumor response, although stable disease was seen in 13 (68%). In another trial, 20 patients received cetuximab, a chimeric monoclonal antibody to the EGFR 71. Once again, no objective responses were observed, although 20 of 23 (87%) had stable disease.…”

Section: Introductionmentioning

confidence: 99%

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Chakraborty²,

et al. 2015

View full text Add to dashboard Cite

BackgroundAdenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this study, recent advances in molecular characterization and in therapeutics are reviewed.MethodsA search of articles in PubMed and of abstracts from national meetings was performed regarding ACC.ResultsRecent genetic analyses found that recurrent chromosome 6:9 translocations in ACC generate an MYB:NFIB gene fusion resulting in overexpression of the MYB oncoprotein. Several other frequent mutations are recently published that may be relevant for drug development. Several trials of targeted drugs are reviewed. Some agents delay tumor progression, but tumor responses remain rare.ConclusionACCs have a characteristic chromosomal translocation, but also frequently pick up additional mutations. Clinical research is limited by the rarity and slow growth of ACC. Several ongoing trials are testing agents that inhibit fibroblast growth factor receptor signaling or other signaling pathways. Novel treatments based on the recently sequenced tumor genome are under development. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. 38: 620–627, 2016

show abstract

“…It should be noted, however, that chemotherapy can offer symptomatic relief without objective tumor response. 1,14,37 Our surgical strategy resulted in no mortality and minimal lasting morbidity across > 70 procedures. Complications ranged from temporary postoperative respiratory failure, neck hematoma requiring evacuation, enopthalmos, to infection.…”

Section: Discussionmentioning

confidence: 91%

Adenoid cystic carcinoma of the skull base: results with an aggressive multidisciplinary approach

Ramakrishna¹,

Raza²,

Kupferman

et al. 2016

JNS

View full text Add to dashboard Cite

A denoid cystic carcinoma (ACC) is a locally aggressive salivary gland malignancy prone to perineural invasion and metastasis. Local recurrences often involve the skull base, whereas distant metastases most frequently involve the lung, bones, and liver. 3,4,27,43,45 Standard therapy for this malignancy has most commonly included a strategy of local resection followed by adjuvant radiation therapy. 6,13,16,17,23,24,28,30,35,38,39,43,46,47,52 Chemotherapy using agents such as carboplatinum and paclitaxel has been used, but with limited results. 2,11,12,15,26,27,36,41,44,[48][49][50] ACC can arise in any salivary gland, both major and minor. Consequently, these tumors can be located in the tongue, trachea, palate, larynx, and paranasal sinuses. 27Tumors in the sinonasal cavity can remain undetected for long periods of time with minimal symptoms. Only after sufficient soft-tissue involvement, bone destruction, or cranial nerve involvement does the malignancy become manifest. Therefore, a strategy of maximal resection with minimal morbidity often presents a substantial therapeutic challenge given the complex anatomy of lesions that involve the paranasal sinuses and extend intracranially into the anterior or middle fossa.abbreviatioNs ACC = adenoid cystic carcinoma; EGFR = epidermal growth factor receptor; ICA = internal carotid artery; OS = overall survival; PFS = progression-free survival; VEGF = vascular endothelial growth factor. submitted October 28, 2014. accepted January 5, 2015. iNclude wheN citiNg Published online August 7, 2015; DOI: 10.3171/2015.1.JNS142462. disclosure The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. results Median follow-up for study patients was 6.75 years. The 5- and 10-year overall survival (OS) rates were 78% and 50%, respectively. Sixty-six percent of patients had progression of their disease. The 5- and 10-year progressionfree survival (PFS) rates were 46.7% and 21.0%, respectively. Gross-total resection was achieved in 75% of patients, with 49% having microscopically negative margins at the time of first operation. On univariate analysis, resections with microscopically negative margins were associated with a significant OS advantage (20.1 ± 3.3 years) compared with resections that left residual disease, even if microscopic (10.3 ± 1.6 years, p = 0.035). In patients who underwent reoperation, the effect persisted, with improved OS in those with negative margins (21.4 ± 0.0 vs 16.7 ± 4.0 years, p = 0.06). The use of adjuvant radiotherapy was associated with an OS advantage (16.2 ± 2.5 vs 5.5 ± 2.2 years, p = 0.03) at initial diagnosis and improved PFS (7.8 ± 1.0 vs 2.1 ± 0.62 years, p = 0.005), whereas repeat irradiation provided no benefit. The use of adjuvant chemotherapy at diagnosis or at recurrence was not associated with any significant advantage. Multivariate analysis revealed margin-negative resection at initial operation and at recurrence retained OS significance, even after controlling...

show abstract

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

Cited by 191 publications

References 18 publications

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Adenoid cystic carcinoma of the skull base: results with an aggressive multidisciplinary approach

Contact Info

Product

Resources

About